Advanced science (Weinheim, Baden-Wurttemberg, Germany)Dec 12, 2025

Boosting a Protective Protein in Brain Support Cells May Improve Clearing of Alzheimer's Amyloid in Mice

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

Astrocyte-targeted Mt3 activation by CRISPRa lipid nanocomplexes enhanced amyloid-beta clearance in an Alzheimer's disease mouse model.

Evidence

Preclinical in vivo mouse experiments used stereotaxic delivery to upregulate Mt3 in astrocytes and measured Aβ uptake and plaque accumulation.

Caveat

The evidence is regional mouse-brain delivery and plaque endpoints, not human safety, cognition, or disease-modifying efficacy.

Simplified

Metallothionein 3 (Mt3) is crucial for cellular homeostasis and neuroprotection, with accumulating evidence linking it to amyloid-beta (Aβ) clearance by astrocytes. This study developed a CRISPR activator (CRISPRa) system using lipid nanoparticles to selectively upregulate Mt3 in astrocytes, aiming to enhance Aβ endocytosis in an Alzheimer's disease (AD) mouse model. To directly assess the therapeutic potential of Mt3 activation in a specific brain region, stereotaxic injection is utilized to deliver the CRISPRa lipid nanocomplexes. This approach enabled precise in vivo brain delivery and Mt3 activation. The findings reveal that CRISPRa lipid nanocomplex-mediated Mt3 upregulation significantly boosts Aβ uptake by astrocytes, leading to a marked reduction in Aβ plaque accumulation in AD mouse brains. These results highlight CRISPRa lipid nanocomplex-mediated Mt3 targeting as a promising strategy to enhance endogenous Aβ clearance, presenting a novel therapeutic avenue for AD.